Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensifi-cation. Among 901 patients under age 21 years, 5-year survival w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lange, Beverly J., Smith, Franklin O., Feusner, James, Barnard, Dorothy R., Dinndorf, Patricia, Feig, Stephen, Heerema, Nyla A., Arndt, Carola, Arceci, Robert J., Seibel, Nita, Weiman, Margie, Dusenbery, Kathryn, Shannon, Kevin, Luna-Fineman, Sandra, Gerbing, Robert B., Alonzo, Todd A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2008
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214754/
https://ncbi.nlm.nih.gov/pubmed/18000167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-084293
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares